ROYALTY MONETIZATIONUP TO $110 MILLION*
RELISTOR® (methylnaltrexone bromide) is a peripheral acting mu-opioid receptor antagonist (“PAMORA”) approved by the FDA and marketed by Bausch Health Companies to treat opioid-induced constipation (“OIC"), a long-lasting and potentially debilitating side effect of opioid therapy for millions of patients suffering from chronic pain. Relistor is the only PAMORA approved for OIC in palliative care and non-cancer pain patients and is available in both subcutaneous and oral formulations.
HCRx acquired Lantheus’ tiered, sales-based royalty rights on worldwide net sales of RELISTOR® while Lantheus retains the rights to future sales-based milestone payments. The RELISTOR® royalties were a non-core asset for Lantheus and their monetization enables the company to enhance its focus on its core radiopharmaceutical business, including continued investment to advance its innovative pipeline.
Note: This transaction also appears in the Royalty Monetization section under RELISTOR.
*The $110 million includes the value of the initial royalty payment, which was netted from the amount paid at closing